Morgan Stanley Biotechnology: Takeaways from MS West Coast Biotech Bus Tour
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
Morgan Stanley recently published key takeaways from its West Coast Biotech Bus Tour, summarizing meetings with multiple biotechnology companies regarding pipeline progress, regulatory dynamics, and commercial prospects. Highlighted firms include Argenx, BioMarin, and Exelixis, spanning therapeutic areas such as autoimmunity, rare diseases, and oncology. The report maintains a constructive outlook on the sector, noting vigorous innovation and improving commercialization capabilities. Argenx demonstrated the potential of Vyvgart in chronic inflammatory demyelinating polyneuropathy, with approval anticipated in 2026. BioMarin reported robust sales growth for Voxzogo in children with achondroplasia, achieving $500 million in 2025 revenue. Exelixis continues to solidify the leading position of Cabometyx in renal cell carcinoma, supported by positive combination therapy data. Additionally, several companies are advancing gene editing and cell therapies. For example, CRISPR Therapeutics showed curative potential with CTX001 in sickle cell disease. The regulatory environment appears increasingly accommodating, with the FDA expanding the use of accelerated approval pathways. While the biotechnology sector currently trades below historical valuation averages, merger and acquisition activity is showing clear signs of recovery. The analysis highlights upcoming data catalysts expected in the second half of 2026, including late-stage clinical results and long-term follow-up data that could significantly revalue participating companies.